Pulmonx (FRA:4NI) Tariff Resilience Score: 5/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4NI Pulmonx Corp FRA:4NI
49 GF Score
Price €1.22
GF Value €6.24
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pulmonx Tariff Resilience Score?

Pulmonx FRA:4NI -1.61% 49 Tariff Resilience Score is 5 as of Jul. 18, 2026. GuruFocus rates FRA:4NI with a GF Score™ of 49/100 and a GF Value™ of €6.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 834 Medical Devices & Instruments companies, Pulmonx ranks better than 79.26% on this metric.

Pulmonx has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Pulmonx has Pulmonx Corp's medical devices are subject to tariffs on imported components. While it has some pricing power, its reliance on specific suppliers limits flexibility. Historical impacts have been moderate, with ongoing efforts to diversify suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pulmonx might have Average Resilient.

Pulmonx  (FRA:4NI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pulmonx Tariff Resilience Score Related Terms

FRA:4NI vs MDAI, QTI, COCH: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Pulmonx's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulmonx Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pulmonx's Tariff Resilience Score falls into.


FRA:4NI
49GF Score
Pulmonx Corp FRA:4NI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Pulmonx (FRA:4NI) has a Tariff Resilience Score of 5 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pulmonx ranks #173 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Pulmonx's Tariff Resilience Score too high?
Pulmonx's current Tariff Resilience Score is 5. Based on the distribution chart, Pulmonx ranks #173 out of 834 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Tariff Resilience Score compare to MDAI and QTI?
According to the Medical Devices & Instruments industry distribution chart, Pulmonx ranks #173 out of 834 companies for Tariff Resilience Score. This places Pulmonx in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Pulmonx's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (FRA:4NI) is currently considered Possible Value Trap. The stock's GF Value™ is €6.24, compared to a current price of €1.22 — trading 80.4% below its estimated fair value. The current Tariff Resilience Score is 5. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pulmonx (FRA:4NI), the current Tariff Resilience Score is 5 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (FRA:4NI) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of €1.22 is trading 80.4% below its estimated GF Value™ of €6.24. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for FRA:4NI:

  • Tariff Resilience Score: 5
  • GF Value™: €6.24 vs. price of €1.22 (80.4% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the FRA:4NI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Other Exchanges LUNG:USA4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score

Get the complete analysis for FRA:4NI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price
€6.24
GF Value